Adagene provides a dynamic precision antibody platform that combines AI‑driven discovery, computational biology, and protein motion insights to engineer multi‑purpose antibodies with novel mechanisms of action. Its proprietary formats—NEObody™, SAFEbody®, and POWERbody™—enable targeted epitope binding, conditional activation in the tumor microenvironment, and enhanced safety and efficacy for oncology therapeutics. The company partners with pharma and biotech firms to accelerate development of these engineered antibodies for solid tumors and lymphomas.
Funding
$25M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
SFounders
Product
Problem
Current antibody therapeutics often face limitations in safety and efficacy due to static designs that cannot optimally engage dynamic protein conformations or the tumor microenvironment, leading to suboptimal clinical outcomes for cancer patients.
Solution
Adagene leverages a dynamic precision antibody platform that integrates computational biology, artificial intelligence, and protein motion insights to design multi‑purpose antibodies with novel mechanisms of action. The platform generates antibodies that can precisely target unique epitopes, mask activity until reaching the tumor microenvironment, and become locally activated to enhance therapeutic index. Proprietary formats such as NEObody™, SAFEbody®, and POWERbody™ enable agonistic, antagonistic, and conditional activation functions within a single molecule. This approach produces candidates with improved safety profiles and stronger anti‑tumor activity, advancing them through clinical development for solid tumors and lymphomas. Strategic global partnerships extend the technology to antibody‑drug conjugates and combination regimens, accelerating translation of these engineered antibodies into clinical use.
Target Audience
Primary customers are pharmaceutical and biotech companies seeking advanced antibody platforms for oncology immunotherapy development, as well as clinical researchers pursuing novel immune‑modulating agents.
Features
- NEObody™ technology that targets unique epitopes to create novel agonist or antagonist functions
- SAFEbody® precision‑masking platform that conditionally activates antibodies within the tumor microenvironment to reduce systemic toxicity
- POWERbody™ format combining masking and local activation for enhanced efficacy across multiple antibody modalities
- AI‑driven antibody discovery pipeline (Dynamic Precision Library) that predicts protein conformational states and optimizes binding characteristics
- Integrated computational and structural biology workflow enabling rapid generation of first‑in‑class therapeutic candidates
- Clinical‑stage assets (e.g., ADG106 CD137 agonist, ADG116 CTLA‑4 antagonist, ADG126 SAFEbody® CTLA‑4) with differentiated mechanisms and ongoing trials